Did you know this truth about HbA1c?
10 New FDA-Approved Endocrinology Drugs
Since June of 2014, the US FDA has approved a number of drugs for a variety of endocrine-related diseases. Here are 10 of them.
We Don't Control the Numbers
While we are increasingly evaluated on numbers—A1c, blood pressure, LDL—these parameters are largely outside of our direct control. Mr M is a case in point.
7 Important Questions on Using SGLT2 Inhibitors in Elderly Patients
There are pros and cons to using SGLT2 inhibitors in the elderly. Are you familiar with both? Find out with 7 quick multiple choice questions.
GLP-1 Receptor Agonists and Cardiovascular Outcomes: 3 Studies
Cardiovascular disease is the underlying cause of death in more than 60% of patients with T2DM. GLP-1 receptor agonists have shown promising cardioprotective effects.
Type 2 Diabetes in a 76-Year-Old Man: Which Drug to Add On?
John is an active older man whose A1c has gone from 6.8% to 7.6% since his last follow-up visit. He refuses to get involved in any “needle business.” What’s next?
SGLT2 Inhibitor Q & A
Four questions for you to answer, four facts you need to know.
No Risk of Acute Pancreatitis Seen with Incretin-Based Therapies
Results of a population-based case-control study point to a general underlying diabetes effect on pancreatitis risk, rather than a specific drug effect.
SGLT2 Inhibitors and Cancer: What's the Risk?
The 3 FDA-approved sodium glucose co-transporter 2 inhibitors remain under close post-marketing scrutiny. These 7 slides distill for you all the cancer risk information to date.
Weight Loss Before Bariatric Surgery in T2DM: GLP-1 Agonist Gets it Done
Pre-surgical weight loss in obese patients with type 2 diabetes reduces perioperative risk. The dual benefits of GLP-1 agonists offer promise to this hard-to-treat population.
By clicking Accept, you agree to become a member of the UBM Medica Community.